AVRX Avalon Pharmaceuticals (MM)

Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it is scheduled to release financial results for the first quarter of 2008 on Wednesday, May 7, 2008 after the close of the U.S. financial markets. The Company will also host a conference call on Thursday, May 8, 2008 at 8:30 am Eastern Time to provide a company update and discuss the financial results for the quarter. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet or by dialing the numbers listed below. Conference Call details: Dial-In: � (877) 419-6597 (U.S.) (719) 325-4858 (International) � Passcode: 4845885 � Webcast: To access the call by live webcast, please visit the Investor Relations section of our website at http://www.Avalonrx.com. An archived version of the webcast will be available for 30 days. About Avalon Pharmaceuticals Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon�s lead product candidate, AVN944,�an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways,�discovery programs�for�inhibitors of�the Survivin�and Myc�pathways and partnerships with Merck, AstraZeneca/MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx� is the company�s proprietary platform�which is based on�large-scale�biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, MD.